# Product Strategy Report: Evolving into Precision Oncology
## Expanding the Genomic Research Copilot for Cancer Therapy Design

**Agent:** Senior Product Manager & Oncology Drug Development Strategist  
**Date:** September 2026  
**Scope:** Market analysis, new module design, GTM strategy, and risk assessment

---

## EXECUTIVE SUMMARY

The recent high-profile success stories of N-of-1 cancer cures — such as a virologist successfully treating her own breast cancer with engineered oncolytic viruses, and patients cured via precise CRISPR-mediated correction of driver mutations — represent an inflection point in medicine. The bottleneck for scaling these personalized, interventional oncology treatments is no longer strictly biological; it is **computational**.

The existing Genomic Research Copilot has established a robust foundation: patient-specific genomic reconstitution, off-target safety screening, and a cryptographic audit trail. By pivoting this platform toward personalized oncology, we transition from a general research tool into a definitive **Interventional Oncology Design Engine**.

---

## SECTION 1: Market Landscape — Oncology Genomics Tools

### Current State of Computational Tools
The precision oncology market is currently dominated by **diagnostic** platforms. Key players like Foundation Medicine, Guardant Health, and Tempus have built massive businesses in a precision oncology market expected to surpass **$100 billion by 2030** by answering one question: *"What mutation does this tumor have?"*

However, when a researcher wants to design a bespoke CRISPR therapy or an engineered virus to *attack* that specific mutation, they are forced into fragmented, unoptimized workflows. They manually cross-reference tumor VCFs with generic tools like Benchling, run off-target analyses on separate platforms (like Cas-OFFinder), and assemble their own viral backbones.

### The Oncolytic Virus Tool Gap
Computational tools for **oncolytic virus engineering** are virtually non-existent in the commercial software space. Viral design is currently a highly manual, artisanal process confined to academic labs and niche biotech R&D departments. This is a massive unmet need that represents an early-mover opportunity.

### The Specific Opportunity We Can Own
The Genomic Research Copilot can own the **Interventional Design Layer**. While Tempus and Foundation provide the diagnostic read (the "map"), our platform becomes the standard engine to design the "missile." Our core architecture — which already reconstitutes patient-specific genomes instead of relying solely on the GRCh38 reference — is exactly what is required to design therapeutics that attack tumor neoantigens without harming healthy somatic tissue.

> **The Gap We Fill:** "I know WHAT mutation my patient has (Foundation Medicine says KRAS G12D). But HOW do I design a CRISPR guide or viral vector that specifically targets that mutation in THIS patient's unique genome?"

---

## SECTION 2: Two New Product Modules to Build

### Module A: OncoCRISPR Designer

**What it will do:**
This module will ingest paired VCFs (Tumor Biopsy vs. Healthy Germline). It will scan the somatic mutations to identify actionable oncogenic drivers (e.g., KRAS G12D, BRCA2, TP53, EGFR). It will then autonomously design CRISPR/Cas9 or Prime Editing guides that selectively target the mutant allele.

**Unique Differentiator — Allele-Specific Precision:**
Standard CRISPR tools design against a reference genome. The OncoCRISPR Designer will leverage our existing patient-specific reconstitution engine to ensure guides have high cleavage efficiency on the tumor allele (perfect match) while possessing critical seed-region mismatches against the patient's healthy germline allele — guaranteeing healthy tissues are spared.

**UX Vision:**
A split-screen **Tumor Mutational Burden (TMB) Dashboard**. Researchers visualize the wildtype locus versus the tumor locus side-by-side, complete with allele-specific Azimuth efficiency scores and base-editing outcome predictions. Color-coded tiers (OncoKB Tier 1/2/3) instantly communicate clinical actionability.

**Cancer Types Supported (Phase 1):**
- Non-small cell lung cancer (EGFR exon 19 del, BRAF V600E)
- Colorectal cancer (KRAS G12D/V, NRAS)
- Pancreatic ductal adenocarcinoma (KRAS G12D)
- Ovarian/breast cancer (BRCA1/2 mutations)
- Hematological malignancies (BCL2, IDH1/2)

---

### Module B: OncoViral Therapy Planner

**What it will do:**
A first-in-class recommendation engine for oncolytic virotherapy. Based on the patient's tumor type and microenvironment profile, the planner will:
1. Recommend the optimal viral backbone (Adenovirus, HSV-1, Vaccinia, NDV, VSV)
2. Design tumor-specific synthetic promoters (so the virus only replicates in cells overexpressing specific oncogenes, e.g., TERT)
3. Plan payload insertions (e.g., knocking in GM-CSF or IL-12 to trigger a systemic T-cell response against the tumor)
4. Calculate immunogenicity risk for the specific patient's immune status

**Integration with Existing Architecture:**
This integrates directly with our existing *Wet-Lab & Delivery Studio*. Instead of just recommending AAVs or LNPs, the system outputs complete viral assembly strategies — which viral deletion cassettes to use, which promoter sequences to insert, and which BSL-2 containment protocols are required for wet-lab validation.

---

## SECTION 3: User Journey for a Cancer Researcher

**Persona:** Dr. Elena Rostova, Lead Translational Investigator at a major cancer center.

**Step 1 — Paired Intake:**
Dr. Rostova uploads the patient's paired genomic data (Germline VCF from blood + Tumor Biopsy VCF from tissue sample) into the expanded *Sample Intake* module. The platform automatically subtracts germline variants, isolating the pure somatic tumor mutation profile.

**Step 2 — Driver Mutation Identification:**
The platform cross-references somatic variants against COSMIC and OncoKB, flagging a highly targetable KRAS G12D driver mutation at 78% Variant Allele Frequency (indicating it is a truncal, clonal mutation present in the vast majority of tumor cells).

**Step 3 — Parallel Therapy Design:**
- She opens **OncoCRISPR Designer**, which instantly generates Prime Editing pegRNAs designed to correct the G12D mutation back to wildtype, specifically mapped against this patient's unique VCF context. The guide is engineered with a C→T mismatch in the seed region at position 8, ensuring zero cutting efficiency on the healthy KRAS wildtype allele.
- She simultaneously opens the **OncoViral Therapy Planner** to design an adjuvant viral therapy: an HSV-1 vector engineered with a synthetic TERT promoter that only fires in the presence of hyperactive KRAS signaling, pre-arming the tumor microenvironment before CRISPR delivery.

**Step 4 — Safety Verification:**
She runs the *Off-Target Genome Scan*, checking CRISPR guides against both the patient's germline and the reconstructed tumor genome (with CNVs). The system flags no high-risk off-target sites.

**Step 5 — Expert Review & Export:**
Dr. Rostova completes the expanded Oncology Expert Review checklist (6-point, tumor-specific). The system outputs an FDA-ready, cryptographically hashed PDF dossier for IRB submission and companion synthesis orders for the vector core.

**Total time from upload to validated design: Under 4 hours** (vs. industry average of 2–3 weeks of manual work).

---

## SECTION 4: Go-To-Market Strategy

### Target Buyers
1. **Cancer Hospitals with Translational Research Arms:** MD Anderson, MSKCC, Dana-Farber, Mayo Clinic — institutions pioneering N-of-1 personalized cell and gene therapies where the workflow time savings are most valuable
2. **Oncology CROs:** Organizations (e.g., Parexel, ICON) that need compliant, repeatable platforms to design and validate therapies for their biotech clients
3. **Pharma Oncology Divisions:** Early-stage pipeline acceleration for Phase I/II oncology gene therapy programs

### Pricing Model (B2B SaaS)
- **Enterprise Clinical License:** $150,000/year base platform fee for dedicated, on-premise or VPC deployment (critical for data privacy with tumor PHI)
- **Per-Patient Processing Fee:** $1,500–$3,000 per bespoke therapy design to cover heavy computational workloads (genome-wide off-target scanning against the personalized tumor genome)
- **Academic Research Tier:** $25,000/year for non-commercial academic research use with publication attribution requirement

### Regulatory Pathway
Pursue **FDA Breakthrough Device Designation** as a *Software as a Medical Device (SaMD)*. Because the system strictly formalizes the design and risk-assessment process (including the human-in-the-loop review gate with cryptographic audit trail), it actively assists hospitals in meeting GCP requirements for IND submissions. This could significantly accelerate the FDA pathway — Breakthrough Designation reduces review time from 180 to 90 days.

### Partnership Opportunities
Strategic IP partnerships with:
- **Oncolytic Virus Pioneers:** Mustang Bio, Vyriad, Agenus, Replimune — by integrating their proprietary viral backbones into the recommendation engine, we drive adoption while facilitating royalty agreements
- **Diagnostic Platforms:** Tempus, Foundation Medicine — as a downstream therapeutic design layer that complements their diagnostic read
- **Synthesis Partners:** Twist Bioscience, GenScript — for integrated 1-click ordering of custom viral components and CRISPR reagents

---

## SECTION 5: Risk Assessment & Mitigation

### Risk 1: Clinical Trial Liability
- **The Risk:** An AI-designed guide RNA or viral vector causes a lethal off-target mutation or unchecked viral replication in a patient, resulting in catastrophic liability.
- **Mitigation:** Strict enforcement of the preclinical disclaimer. The mandatory Expert Review Gate and SHA-256 audit trail shift clinical liability strictly to the institutional investigator, mathematically proving they reviewed the data and authorized wet-lab validation prior to any clinical administration. This is the model used by Illumina's MiSeq Reporter — the software generates the analysis; the clinician makes the decision.

### Risk 2: Data Sensitivity (Tumor PHI)
- **The Risk:** Tumor and germline VCFs represent the most highly identifiable and sensitive Protected Health Information (PHI). Cloud breaches would be disastrous.
- **Mitigation:** The platform's existing architecture is perfectly suited for on-premise/edge deployment. By deploying the FastAPI/SQLite backend locally behind hospital firewalls, patient genomic data never traverses the public internet.

### Risk 3: Competitive Threats
- **The Risk:** Benchling could acquire an AI startup and build similar features; Tempus could pivot downstream into therapeutic design.
- **Mitigation:** Speed to market and specialization. Benchling is a generalized ELN; Tempus is diagnostic. By hyper-focusing on patient-specific, sequence-personalized therapeutic design — a technically difficult moat we already possess via the VCF intake module — we establish ourselves as the de facto standard before incumbents can pivot.

---

## Conclusion

The Genomic Research Copilot is at a once-in-a-decade market timing opportunity. The breakthroughs in oncolytic virotherapy (Dr. Beata Halassy) and somatic CRISPR correction are creating urgent demand for exactly the kind of personalized, computationally rigorous, auditable design environment this platform provides. The first company to productize this workflow at clinical grade will dominate precision oncology computational infrastructure for the next decade.
